UCLA Journal of Radiation Oncology SPRING 2024 - Flipbook - Page 42
UCLA RADIATION ONCOLOGY JOURNAL
19. C Hehakaya, JR van der Voort van Zyp, JJW Lagendijk, et al. Problems and promises of introducing the
magnetic resonance imaging linear accelerator into routine care: The case of prostate cancer. Front Oncol, 10
(2020), p. 1741, 10.3389/fonc.2020.01741
20. Treatment Centers. Accessed March 29, 2023. https://www.elekta.com/patients/treatment-centers/
21. MRIdian Treatment Centers. Accessed March 29, 2023. https://viewray.com/mridian-treatment-centers/
22. Davis RL. Department of radiation oncology to install MRIdian Linac system. 2017. Accessed March 29, 2023.
https://radonc.wustl.edu/department-of-radiation-oncology-to-install-new-mridian-linac-system/
23. Hoag Family Cancer Institute. Hoag is revolutionizing cancer therapy., 2021. Accessed March 29, 2023. https://
www.hoag.org/hoag-for-life/hoag-is-revolutionizing-cancer-therapy/
24. ViewRay Inc. Louis Stokes Cleveland VA Medical Center Purchases ViewRay's MRIdian Linac for MRI-guided
radiation therapy. 2020. Accessed March 29, 2023.https://investors.viewray.com/news-releases/news-releasedetails/louis-stokes-cleveland-va-medical-center-purchases-viewrays
25. JW Randall, N Rammohan, IJ Das, et al. Towards accurate and precise image-guided radiotherapy: Clinical
applications of the MR-Linac. J Clin Med, 11 (14) (2022), p. 4044, 10.3390/jcm11144044
26. J Keyriläinen, O Sjöblom, S Turnbull-Smith, et al. Clinical experience and cost evaluation of magnetic
resonance imaging -only workflow in radiation therapy planning of prostate cancer. Phys Imaging Radiat Oncol,
19 (2021), 10.1016/j.phro.2021.07.004
27. E Persson, N Svanberg, J Scherman, et al. MRI-only radiotherapy from an economic perspective: Can
new techniques in prostate cancer treatment be cost saving?. Clin Transl Radiat Oncol, 38 (2023), pp. 183-187,
10.1016/j.ctro.2022.11.012
28. C Greco, O Pares, N Pimentel, et al. Safety and efficacy of virtual prostatectomy with single-dose radiotherapy
in patients with intermediate-risk prostate cancer: Results from the PROSINT phase 2 randomized clinical trial.
JAMA Oncol, 7 (5) (2021), pp. 700-708, 10.1001/jamaoncol.2021.0039
29. Y Alayed, P Cheung, W Chu, et al. Two StereoTactic ablative radiotherapy treatments for localized prostate
cancer (2STAR): Results from a prospective clinical trial. Radiother Oncol, 135 (2019), pp. 86-90, 10.1016/j.
radonc.2019.03.002
30. SL Wang, H Fang, YW Song, et al. Hypofractionated versus conventional fractionated postmastectomy
radiotherapy for patients with high-risk breast cancer: A randomised, non-inferiority, open-label, phase 3 trial.
Lancet Oncol, 20 (3) (2019), pp. 352-360, 10.1016/S1470-2045(18)30813-1
31 Chin R. Stereotactic body radiation therapy using HyperArc in treating patients with recurrent head and neck
cancer. Accessed March 29, 2023. https://clinicaltrials.gov/ct2/show/NCT03892720
32 RR Bahadoer, EA Dijkstra, B van Etten, et al. Short-course radiotherapy followed by chemotherapy before total
mesorectal excision (TME) versus preoperative chemoradiotherapy, TME, and optional adjuvant chemotherapy
in locally advanced rectal cancer (RAPIDO): A randomised, open-label, phase 3 trial. Lancet Oncol, 22 (1) (2021),
pp. 29-42, 10.1016/S1470-2045(20)30555-6
33. A Kalbasi, M Kamrava, FI Chu, et al. A phase II trial of 5-day neoadjuvant radiotherapy for patients with highrisk primary soft tissue sarcoma. Clin Cancer Res, 26 (8) (2020), pp. 1829-1836, 10.1158/1078-0432.CCR-19-3524
34. AU Kishan, J Lamb, M Casado, et al. Magnetic resonance imaging-guided versus computed tomographyguided stereotactic body radiotherapy for prostate cancer (MIRAGE): Interim analysis of a phase III randomized
trial. J Clin Oncol, 40 (6 suppl) (2022), pp. 365-373, 10.1200/jco.2022.40.6_suppl.255
35. TN Sholklapper, ML Creswell, AT Payne, et al. Patient-reported financial burden following stereotactic body
radiation therapy for localized prostate cancer. Front Oncol, 12 (2022), Article 852844, 10.3389/fonc.2022.852844
36. S McClelland, EE Harris, DE Spratt, et al. Navigator-assisted hypofractionation (NAVAH) to address radiation
therapy access disparities facing African-Americans with breast cancer. Rep Pract Oncol Radiother, 27 (3) (2022),
pp. 583-588, 10.5603/RPOR.a2022.0064
37. LA Gharzai, R Jagsi. Incorporating financial toxicity considerations into clinical trial design to facilitate
patient-centered decision-making in oncology. Cancer, 129 (8) (2023), pp. 1143-1148, 10.1002/cncr.34677
38. SY Zafar, AP Abernethy. Financial toxicity, Part I: A new name for a growing problem. Oncology (Williston
Park), 27 (2) (2013), pp. 80-81
39. D Larios, SA Dunn, JH Li, et al. The carbon footprint of radiation oncology on climate change: A model in
early-stage breast cancer. Int J Radiat Oncol Biol Phys, 114 (3, Supplement) (2022), p. S129
40. NJ Coombs, JM Coombs, UJ Vaidya, et al. Environmental and social benefits of the targeted intraoperative
radiotherapy for breast cancer: Data from UK TARGIT-A trial centres and two UK NHS hospitals offering TARGIT
IORT. BMJ Open, 6 (5) (2016), Article e010703, 10.1136/bmjopen-2015-010703
42